Pharmacy Medical News about Macular Degeneration

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Changes in Aqueous Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor after Ranibizumab Alone or Combined with Verteporfin for Exudative Age-related Macular Degeneration
American Journal of Ophthalmology, 08/12/09

Ahn JK et al. – Ranibizumab therapy for CNV secondary to AMD is associated with reduced levels of aqueous VEGF and PEDF regardless of combined therapy with PDT. The reduction levels of VEGF and PEDF are correlated with anatomic improvements in the macula.

<< Previous
A phase II study of sunitinib in patients with recurrent and/or...

Next >>
Facility fees added to patient bills have some crying foul

Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration
Retina, 11/11/09 Relevance Score: 68%

Statin Use and the Incidence of Advanced Age-Related Macular Degeneration in the Complications of Age-Related Macular Degeneration Prevention Trial
Ophthalmology, 10/28/09 Relevance Score: 68%

siRNA therapeutics for age-related macular degeneration: promises and pitfalls
Expert Review of Ophthalmology, 10/22/09 Relevance Score: 68%

Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
American Journal of Ophthalmology, 10/07/09 Relevance Score: 67%

The pathogenic role of the canonical Wnt pathway in age-related macular degeneration
Investigative Ophthalmology and Visual Science, 11/18/09 Relevance Score: 66%